Cargando…

A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma

Malignant peritoneal mesothelioma (MPM) is an aggressive rare malignancy associated with asbestos exposure. A better understanding of the molecular pathogenesis of MPM will help develop a targeted therapy strategy. Oncogene targeted depth sequencing was performed on a tumor sample and paired periphe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Jun, Zhou, Zhan, Tang, Xiao-Jing, Gao, Zhi-Bin, Zhou, Jie, Chen, Shu-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881561/
https://www.ncbi.nlm.nih.gov/pubmed/27187383
http://dx.doi.org/10.3390/ijms17050739
_version_ 1782433985713930240
author Lai, Jun
Zhou, Zhan
Tang, Xiao-Jing
Gao, Zhi-Bin
Zhou, Jie
Chen, Shu-Qing
author_facet Lai, Jun
Zhou, Zhan
Tang, Xiao-Jing
Gao, Zhi-Bin
Zhou, Jie
Chen, Shu-Qing
author_sort Lai, Jun
collection PubMed
description Malignant peritoneal mesothelioma (MPM) is an aggressive rare malignancy associated with asbestos exposure. A better understanding of the molecular pathogenesis of MPM will help develop a targeted therapy strategy. Oncogene targeted depth sequencing was performed on a tumor sample and paired peripheral blood DNA from a patient with malignant mesothelioma of the peritoneum. Four somatic base-substitutions in NOTCH2, NSD1, PDE4DIP, and ATP10B and 1 insert frameshift mutation in BAP1 were validated by the Sanger method at the transcriptional level. A 13-amino acids neo-peptide of the truncated Bap1 protein, which was produced as a result of this novel frameshift mutation, was predicted to be presented by this patient’s HLA-B protein. The polyclonal antibody of the synthesized 13-mer neo-peptide was produced in rabbits. Western blotting results showed a good antibody-neoantigen specificity, and Immunohistochemistry (IHC) staining with the antibody of the neo-peptide clearly differentiated neoplastic cells from normal cells. A search of the Catalogue of Somatic Mutations in Cancer (COSMIC) database also revealed that 53.2% of mutations in BAP1 were frameshift indels with neo-peptide formation. An identified tumor-specific neo-antigen could be the potential molecular biomarker for personalized diagnosis to precisely subtype rare malignancies such as MPM.
format Online
Article
Text
id pubmed-4881561
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48815612016-05-27 A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma Lai, Jun Zhou, Zhan Tang, Xiao-Jing Gao, Zhi-Bin Zhou, Jie Chen, Shu-Qing Int J Mol Sci Article Malignant peritoneal mesothelioma (MPM) is an aggressive rare malignancy associated with asbestos exposure. A better understanding of the molecular pathogenesis of MPM will help develop a targeted therapy strategy. Oncogene targeted depth sequencing was performed on a tumor sample and paired peripheral blood DNA from a patient with malignant mesothelioma of the peritoneum. Four somatic base-substitutions in NOTCH2, NSD1, PDE4DIP, and ATP10B and 1 insert frameshift mutation in BAP1 were validated by the Sanger method at the transcriptional level. A 13-amino acids neo-peptide of the truncated Bap1 protein, which was produced as a result of this novel frameshift mutation, was predicted to be presented by this patient’s HLA-B protein. The polyclonal antibody of the synthesized 13-mer neo-peptide was produced in rabbits. Western blotting results showed a good antibody-neoantigen specificity, and Immunohistochemistry (IHC) staining with the antibody of the neo-peptide clearly differentiated neoplastic cells from normal cells. A search of the Catalogue of Somatic Mutations in Cancer (COSMIC) database also revealed that 53.2% of mutations in BAP1 were frameshift indels with neo-peptide formation. An identified tumor-specific neo-antigen could be the potential molecular biomarker for personalized diagnosis to precisely subtype rare malignancies such as MPM. MDPI 2016-05-14 /pmc/articles/PMC4881561/ /pubmed/27187383 http://dx.doi.org/10.3390/ijms17050739 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lai, Jun
Zhou, Zhan
Tang, Xiao-Jing
Gao, Zhi-Bin
Zhou, Jie
Chen, Shu-Qing
A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
title A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
title_full A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
title_fullStr A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
title_full_unstemmed A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
title_short A Tumor-Specific Neo-Antigen Caused by a Frameshift Mutation in BAP1 Is a Potential Personalized Biomarker in Malignant Peritoneal Mesothelioma
title_sort tumor-specific neo-antigen caused by a frameshift mutation in bap1 is a potential personalized biomarker in malignant peritoneal mesothelioma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881561/
https://www.ncbi.nlm.nih.gov/pubmed/27187383
http://dx.doi.org/10.3390/ijms17050739
work_keys_str_mv AT laijun atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT zhouzhan atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT tangxiaojing atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT gaozhibin atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT zhoujie atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT chenshuqing atumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT laijun tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT zhouzhan tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT tangxiaojing tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT gaozhibin tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT zhoujie tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma
AT chenshuqing tumorspecificneoantigencausedbyaframeshiftmutationinbap1isapotentialpersonalizedbiomarkerinmalignantperitonealmesothelioma